Here’s a roundup of recent clinical trial news:
- Aeolus drug helps "non-human primates" survive lethal radiation
Aeolus Pharmaceuticals Inc. (OTC:AOLS) announced preliminary results showing that AEOL 10150 promotes survival in a proof-of-principle study conducted in a non-human primate model of Pulmonary Acute Radiation Syndrome (ARS). The study included 13 animals, of which 6 were control animals and 7 received AEOL 10150. While none of the six control animals survived the 180-day study period, 2 of the 7 (or 28.5 percent) of the animals receiving drug survived.
- Endologix announces first clinical implant of Ventana stent graft
Endologix Inc. (NSDQ:ELGX), developer of minimally invasive treatments for aortic disorders, announced the first clinical implant of its Ventana fenestrated stent graft at Auckland City Hospital in Auckland, New Zealand.
- Hologic announces five-year results from MammoSite ASBS registry study
Hologic Inc. (NSDQ:HOLX) announced the long-term, five-year results from the American Society of Breast Surgeons MammoSite breast brachytherapy registry trial while showcasing the MammoSite ML system at the 52nd American Society for Radiation Oncology annual meeting in San Diego.
- Atrium announces completion of patient enrollment for the iCARUS covered stent trial for PAD patients who suffer acute or chronic leg pain
Atrium Medical Corp. announced that the final patient was enrolled in the iCAST Atrium Registry Ultrasound Study, a prospective, multi-center clinical trial studying the safety and efficacy of the Atrium iCAST balloon-expandable covered stent in patients with occlusive disease of the iliac artery.
- Bronchial thermoplasty demonstrates long-term asthma control in patients with severe asthma
Boston Scientific Corp. (NYSE:BSX) announced that its newly acquired subsidiary, Asthmatx Inc., presented two-year results from the Asthma Intervention Research 2 (AIR2) Trial demonstrating the long-term safety and effectiveness of bronchial thermoplasty in adult patients with severe asthma.
- CyberKnife radiosurgery for early-stage breast cancer
Accuray Inc. (NSDQ:ARAY) announced studies underway at two leading academic institutions using CyberKnife radiosurgery in breast cancer treatment.
- Penumbra Inc. enrolls first patients in PULSE trial
The stroke teams at the University Hospital Dresden in Dresden, Germany, and the University Hospital Göttingen in Göttingen, Germany, have enrolled the first patients in an international clinical trial to assess the safety and effectiveness of aspiration with the Penumbra system in conjunction with the Pulse flow restoration device.
- Gore launches study of early TIPS therapy for ascites patients
W.L. Gore & Associates announced a new prospective, randomized, multi-center study at the Annual Meeting of the American Assn. for the Study of Liver Diseases. The hypothesis of the study is that early intervention with the Gore Viatorr TIPS endoprosthesis improves transplant-free survival when compared to large volume paracentesis in patients with cirrhosis and difficult to treat ascites.
- Atritech enrolls first patient in Prevail study
Atritech Inc. announced initial enrollment into its confirmatory study, Prevail, comparing the Watchman left atrial appendage closure device to long term warfarin therapy in patients with atrial fibrillation.
- Spectros presents new clinical studies using T-Stat VLS tissue oximeter
Spectros Corp. presented new clinical results using tissue oxygen saturation with the T-Stat VLS tissue oximeter at the San Diego Convention Center during Anesthesiology 2010.
- JenaValve Technology initiates multi-center CE Mark study for its transapical TAVI system
JenaValve Technology Inc. announced the start of its multicenter CE Mark study. The first two implantations of its transapical TAVI system were performed by Dr. Hendrik Treede at the Universitäres Herzzentrum, Hamburg, Germany.